TVGN at a glance
Tevogen Bio Holdings Inc. (TVGN, SEC CIK 1860871) filed its latest 10-K annual report on March 31, 2026, a 10-Q quarterly report on November 16, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of December 31, 2025, 18 institutional investment managers tracked by SignalX reported holding Tevogen Bio Holdings Inc. (TVGN) shares worth $1.2 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 18 funds
- $1.2M · +3 vs prior quarter
- Latest 8-K
- Nov 4, 2026
- Item 5.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material risk-factor changes disclosed, with Item 1A containing no substantive risk-factor text
- Liquidity risk: $144,713 cash versus $6,371,539 current liabilities at September 30, 2026
- Financing risk: $1,651,000 notes payable remained in default following the Merger
- Dilution risk: up to approximately 4.99 million additional shares issuable under the amended Loan Agreement
- Clinical and regulatory risk: TVGN 489 and other candidates may fail development or required regulatory approval
Management Discussion & Analysis
- Revenue $0, unchanged YoY, with no products commercialized
- Operating margin not applicable, operating loss $6.9M vs $5.7M YoY
- Worst expense trend: G&A $3.9M vs $2.6M, driven by stock-based compensation
- Cash $0.1M vs $0.6M at December 31, 2025, operating cash use $7.7M
- Outlook: $28.6M borrowing availability and $7.0M committed grant, clinical trial deferred until manufacturing facility secured
AI summary of the TVGN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Director Susan Podlogar resigned effective November 2, 2026
- Board reduced from six to five directors, reducing governance capacity
Item 3.02: Unregistered Sales of Equity Securities
- Potential equity issuance to lender for debt repayment, creating dilution risk for TVGN shareholders
- Pre-funded warrants may substitute for shares, preserving lender conversion economics while deferring share issuance
Item 1.01: Entry into a Material Definitive Agreement
- Borrowing window extended to May 31, 2029, with post-amendment facility availability capped at $28.6 million
- $7.4 million principal plus $177,880 accrued interest repaid through 1,023,733 shares at $7.40 per share
Item 5.02: Departure/Appointment of Directors or Principal Officers
- CEO Ryan Saadi received 50,000,000 restricted shares, creating substantial potential dilution if the performance condition is achieved
- Vesting requires $1.0 billion aggregate revenue by December 31, 2031, aligning compensation with a long-term growth target
Item EX-99.1: Item EX-99.1
- Nasdaq Global Market compliance restored under the $50 million minimum market value requirement
- Minimum market value of publicly held shares requirement also satisfied
Item 8.01: Other Events
- Tevogen regained compliance with Nasdaq’s $50 million minimum market value requirement under Rule 5450(b)(2)(A)
- Continued listing on The Nasdaq Global Market preserved, reducing delisting risk for TVGN and TVGNW holders
AI summaries of TVGN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for TVGN
Don't miss the next TVGN filing
- Alerts as it files. A push when TVGN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut TVGN, by share count.
- Ask anything. An AI agent that reads every TVGN filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Saadi Ryan H. | A | Nov 2, 2026 | 50,000,000 | - |
| Desai Kirti | A | Sep 14, 2026 | 750,000 | - |
| Saadi Ryan H. | A | Sep 14, 2026 | 8,000,000 | - |
| Goh Keow Lin | A | Sep 11, 2026 | 75,000 | - |
| PODLOGAR SUSAN M | A | Sep 11, 2026 | 75,000 | - |
| Sordillo Victor J. | A | Sep 11, 2026 | 75,000 | - |
| Patton Curtis L. | A | Sep 11, 2026 | 75,000 | - |
| Feike Jeffrey L. | A | Sep 11, 2026 | 75,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$8.8M | -$53.6M | -$26.1M |
| Net Income | -$67K | -$13.7M | -$26.3M |
| Balance Sheet | |||
| Total Assets | $17.0M | $3.5M | $4.4M |
| Equity | -$17.4M | -$6.7M | -$8.2M |
| ROE | 0.4% | 205.7% | 319.1% |
| Per Share | |||
| EPS | $-2.44 | $-0.07 | $-8.08 |
| Cash Flow | |||
| Operating CF | -$1.4M | -$12.0M | -$12.3M |
| CapEx | $133K | - | $64K |
Source: XBRL data in Tevogen Bio Holdings Inc. (TVGN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q4 2025Aggregate TVGN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q4 2025 | 18 | $1.2M |
| Q3 2025 | 15 | $2.7M |
| Q2 2025 | 15 | $4.3M |
| Q1 2025 | 13 | $1.8M |
| Q4 2024 | 9 | $559,000 |
- Goldman Sachs Group+152.6K (+126%)
- Morgan Stanley+123.6K (+98%)
- Vanguard Group Inc+44.7K (+4%)
- Wells Fargo & Co+25.1K (+124%)
- State Street Corp+17.7K (+15%)
- BlackRock−357.4K (-23%)
- BNY Mellon−23.6K (-42%)
- JPMorgan Chase & Co−12.6K (-25%)
- AQR Capital Management−9.8K (-43%)
- Invesco Ltd−6.3K (-35%)
- Citadel Advisors LLC+17.2K
- Prudential Financial+11.5K
- StoneX Group Inc.+10.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 70 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
TVGN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 16, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Nov 4, 2026 | - | - | - |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 8-K | Nov 3, 2026 | - | Analysis | - |
| 8-K | Sep 30, 2026 | - | Analysis | - |
| 4 | Sep 16, 2026 | - | - | - |
| 4 | Sep 16, 2026 | - | - | - |
| 8-K | Sep 16, 2026 | - | Analysis | - |
| 4 | Sep 15, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| 8-K | Sep 10, 2026 | - | Analysis | - |
| 8-K | Aug 26, 2026 | - | Analysis | - |
| 10-Q | Aug 14, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 4 | Jul 10, 2026 | - | - | - |
| 4 | Jul 10, 2026 | - | - | - |
| 4 | Jul 10, 2026 | - | - | - |
| 4 | Jul 10, 2026 | - | - | - |
| 4 | Jul 10, 2026 | - | - | - |
| 4 | Jul 10, 2026 | - | - | - |
| 4 | Jul 10, 2026 | - | - | - |
| 10-Q | May 15, 2026 | Mar 31, 2026 | Analysis |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
TVGN SEC filings: frequently asked questions
Which institutions hold TVGN stock?
As of December 31, 2025, the largest Tevogen Bio Holdings Inc. (TVGN) holders among the 13F filers tracked by SignalX were BlackRock ($395,000), Vanguard Group Inc ($376,000), Goldman Sachs Group ($91,000), Morgan Stanley ($83,000), Northern Trust ($65,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What did TVGN report in its latest 8-K?
Tevogen Bio Holdings Inc. (TVGN) filed an 8-K on November 4, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). Director Susan Podlogar resigned effective November 2, 2026.
What are the latest TVGN SEC filings?
Tevogen Bio Holdings Inc. (TVGN) filed its latest 10-K annual report on March 31, 2026, a 10-Q quarterly report on November 16, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 4, 2026.
What is TVGN's SEC CIK number?
Tevogen Bio Holdings Inc. (TVGN)'s SEC Central Index Key (CIK) is 1860871. EDGAR lists every TVGN filing under that number.
Ask anything about TVGN
The research agent reads TVGN's filings, financials, insider trades and 13F holders, then answers with sources.